BRIEF-Kinnate Biopharma Sells Its Investigational Pan-RAF Inhibitor to Pierre Fabre Laboratories

Reuters03-01

March 1 (Reuters) - Kinnate Biopharma Inc :

* KINNATE BIOPHARMA INC. SELLS ITS INVESTIGATIONAL PAN-RAF INHIBITOR, EXARAFENIB, TO PIERRE FABRE LABORATORIES

* KINNATE BIOPHARMA INC - TRANSACTION IS IN FURTHERANCE OF KINNATE'S PREVIOUSLY ANNOUNCED PURSUIT OF STRATEGIC ALTERNATIVES

* KINNATE BIOPHARMA - ENTERED ASSET PURCHASE AGREEMENT WITH PIERRE FABRE LABORATORIES FOR GLOBAL RIGHTS TO EXARAFENIB AND OTHER PAN-RAF PROGRAM ASSETS

* KINNATE BIOPHARMA INC - PIERRE FABRE LABORATORIES WILL ASSUME 100% OF ONGOING PROGRAM AND COSTS ASSOCIATED WITH ASSETS

* KINNATE BIOPHARMA INC - WILL RECEIVE A TOTAL CONSIDERATION OF UP TO $31 MILLION

* KINNATE BIOPHARMA INC - PIERRE FABRE LABORATORIES WILL ASSUME UP TO $5 MILLION OF TRADE PAYABLES FOR TRANSFERRED ASSETS

* KINNATE BIOPHARMA INC - TRANSACTION IS NOT SUBJECT TO CLOSING CONDITIONS AND CLOSED UPON SIGNING.

* KINNATE BIOPHARMA INC - WILL RECEIVE $30.5 MILLION PAYMENT CONTINGENT UPON EARLIER OF DOSING OF FIRST PATIENT IN FIRST PIVOTAL TRIAL FOR EXARAFENIB

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2416690648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-01 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2416690648","market":"us","top_or_hot":-1,"title":"BRIEF-Kinnate Biopharma Sells Its Investigational Pan-RAF Inhibitor to Pierre Fabre Laboratories","media":"Reuters","content":"<html><body><p>March 1 (Reuters) - Kinnate Biopharma Inc   :</p><p>   * KINNATE BIOPHARMA INC. SELLS ITS INVESTIGATIONAL PAN-RAF INHIBITOR, EXARAFENIB, TO PIERRE FABRE LABORATORIES</p><p>   * KINNATE BIOPHARMA INC - TRANSACTION IS IN FURTHERANCE OF KINNATE'S PREVIOUSLY ANNOUNCED PURSUIT OF STRATEGIC ALTERNATIVES</p><p>   * KINNATE BIOPHARMA - ENTERED ASSET PURCHASE AGREEMENT WITH PIERRE FABRE LABORATORIES FOR GLOBAL RIGHTS TO EXARAFENIB AND OTHER PAN-RAF PROGRAM ASSETS</p><p>   * KINNATE BIOPHARMA INC -  PIERRE FABRE LABORATORIES WILL ASSUME 100% OF ONGOING PROGRAM AND COSTS ASSOCIATED WITH ASSETS</p><p>   * KINNATE BIOPHARMA INC - WILL RECEIVE A TOTAL CONSIDERATION OF UP TO $31 MILLION</p><p>   * KINNATE BIOPHARMA INC - PIERRE FABRE LABORATORIES WILL ASSUME UP TO $5 MILLION OF TRADE PAYABLES FOR TRANSFERRED ASSETS</p><p>   * KINNATE BIOPHARMA INC - TRANSACTION IS NOT SUBJECT TO CLOSING CONDITIONS AND CLOSED UPON SIGNING.</p><p>   * KINNATE BIOPHARMA INC -  WILL RECEIVE $30.5 MILLION PAYMENT  CONTINGENT UPON EARLIER OF DOSING OF FIRST PATIENT IN FIRST PIVOTAL TRIAL FOR EXARAFENIB</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Kinnate Biopharma Sells Its Investigational Pan-RAF Inhibitor to Pierre Fabre Laboratories</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Kinnate Biopharma Sells Its Investigational Pan-RAF Inhibitor to Pierre Fabre Laboratories\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-01 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 1 (Reuters) - Kinnate Biopharma Inc   :   * KINNATE BIOPHARMA INC. SELLS ITS INVESTIGATIONAL PAN-RAF INHIBITOR, EXARAFENIB, TO PIERRE FABRE LABORATORIES   * KINNATE BIOPHARMA INC - TRANSACTION ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNTE","symbol_name":"Kinnate BioPharma Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2416690648","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2416690648","pubTimestamp":1709300009,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 1  - Kinnate Biopharma Inc   :   * KINNATE BIOPHARMA INC. SELLS ITS INVESTIGATIONAL PAN-RAF INHIBITOR, EXARAFENIB, TO PIERRE FABRE LABORATORIES   * KINNATE BIOPHARMA INC - TRANSACTION IS IN FURTHERANCE OF KINNATE'S PREVIOUSLY ANNOUNCED PURSUIT OF STRATEGIC ALTERNATIVES   * KINNATE BIOPHARMA - ENTERED ASSET PURCHASE AGREEMENT WITH PIERRE FABRE LABORATORIES FOR GLOBAL RIGHTS TO EXARAFENIB AND OTHER PAN-RAF PROGRAM ASSETS   * KINNATE BIOPHARMA INC -  PIERRE FABRE LABORATORIES WILL ASSUME 100% OF ONGOING PROGRAM AND COSTS ASSOCIATED WITH ASSETS   * KINNATE BIOPHARMA INC - WILL RECEIVE A TOTAL CONSIDERATION OF UP TO $31 MILLION   * KINNATE BIOPHARMA INC - PIERRE FABRE LABORATORIES WILL ASSUME UP TO $5 MILLION OF TRADE PAYABLES FOR TRANSFERRED ASSETS   * KINNATE BIOPHARMA INC - TRANSACTION IS NOT SUBJECT TO CLOSING CONDITIONS AND CLOSED UPON SIGNING.   * KINNATE BIOPHARMA INC -  WILL RECEIVE $30.5 MILLION PAYMENT  CONTINGENT UPON EARLIER OF DOSING OF FIRST PATIENT IN FIRST PIVOTAL TRIA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KNTE":"Kinnate BioPharma Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Kinnate Biopharma向Pierre Fabre Laboratories出售其研究中的泛RAF抑制剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNTE":1},"content_text":"March 1 (Reuters) - Kinnate Biopharma Inc   :   * KINNATE BIOPHARMA INC. SELLS ITS INVESTIGATIONAL PAN-RAF INHIBITOR, EXARAFENIB, TO PIERRE FABRE LABORATORIES   * KINNATE BIOPHARMA INC - TRANSACTION IS IN FURTHERANCE OF KINNATE'S PREVIOUSLY ANNOUNCED PURSUIT OF STRATEGIC ALTERNATIVES   * KINNATE BIOPHARMA - ENTERED ASSET PURCHASE AGREEMENT WITH PIERRE FABRE LABORATORIES FOR GLOBAL RIGHTS TO EXARAFENIB AND OTHER PAN-RAF PROGRAM ASSETS   * KINNATE BIOPHARMA INC -  PIERRE FABRE LABORATORIES WILL ASSUME 100% OF ONGOING PROGRAM AND COSTS ASSOCIATED WITH ASSETS   * KINNATE BIOPHARMA INC - WILL RECEIVE A TOTAL CONSIDERATION OF UP TO $31 MILLION   * KINNATE BIOPHARMA INC - PIERRE FABRE LABORATORIES WILL ASSUME UP TO $5 MILLION OF TRADE PAYABLES FOR TRANSFERRED ASSETS   * KINNATE BIOPHARMA INC - TRANSACTION IS NOT SUBJECT TO CLOSING CONDITIONS AND CLOSED UPON SIGNING.   * KINNATE BIOPHARMA INC -  WILL RECEIVE $30.5 MILLION PAYMENT  CONTINGENT UPON EARLIER OF DOSING OF FIRST PATIENT IN FIRST PIVOTAL TRIAL FOR EXARAFENIBSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2416690648"}